Brief: Research Ethics Board approves amendment to Canadian Treatments for COVID-19 Trial to include LSALT Peptide
04/01/2022 12:47
Jan 4 (Reuters) - Arch Biopartners Inc ARCH.V :
* RESEARCH ETHICS BOARD APPROVES AMENDMENT TO CANADIAN
TREATMENTS
FOR COVID-19 (CATCO) TRIAL TO INCLUDE LSALT PEPTIDE (METABLOK)
* ARCH BIOPARTNERS INC - CATCO LEADERSHIP WILL NOW SEEK
HEALTH
CANADA APPROVAL BEFORE COMMENCING DOSING OF LSALT IN NEW ARM OF
TRIAL
Source text for Eikon: ID:nGNX8BCjCD
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide